Atlas Trials

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Clinical trial NCT04341116 · COMPLETED

Trial details

NCT number
NCT04341116
Sponsor
I-Mab Biopharma US Limited
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Coronavirus Disease 2019 COVID-19
Start date
2020-04-11
Primary completion
2022-02-07
Enrollment
149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.